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Severity of depression, as reflected by total scores on depression rating 
scales, has been established as one of several major sources of variance 
associated with hypothalamic-pituitary-adrenal axis dysregulation in 
patients with major depressive disorder. To determine which of the symptoms 
comprising clinically defined severity of illness contribute most to this re- 
lationship, we studied the associations between postdexamethasone plasma 
cortisol levels and components of the Hamilton Rating Scale for 
Depression (HRSD) in 114 patients with major depressive disorder. At 
pretreatment baseline, severity of depression was modestly but significantly 
correlated with postdexamethasone plasma cortisol; a large part of this 
relationship was associated with the anxiety components of the HRSD. 
When relationships between postdexamethasone plasma cortisol and 
severity measures were studied longitudinally during treatment, this con- 
tribution of the anxiety items persisted. The anxiety associated with depres- 
sion appears to be a major clinical factor associated with the hypothalamic- 
pituitary-adrenal axis dysregulation in major depressive disorder. I 
Dy sregulation of the hypothalamic-pituitary-adrenal 
(HPA) axis occurs in many individuals with major 
depressive disorder (1-5). This disturbance has 
most often been studied by the dexamethasone sup- 
pression test (DST), although other challenge 
paradigms, such as corticotropin-releasing hormone 
(CRH) infusions, have been employed (6-8). The 
DST was originally conceived as a possible biologi- 
cal correlate specific to endogenous depression (1). 
As various investigative groups have accumulated 
neuroendocrine data on large groups of patients, 
however, it has become apparent that this dysregu- 
lation is complex and has many determinants, and 
the DST may better serve as a paradigm to study 
pathophysiology rather than as a diagnostic test. 
Multiple clinical factors influence postdexa- 
methasone plasma cortisol levels. These include 
severity of depressive episode (9-19), age (20-23), 
history of recent weight loss (24,25), the presence of 
delusions (26-29), and recent use or withdrawal of 
psychotropic medication (30-33). Severity of de- 
pressive symptoms, as reflected by rating scale 
scores, is positively correlated with plasma post- 
dexamethasone cortisol levels (9-14), as well as with 
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circulating levels of pituitary hormones associated 
with the HPA axis (11). This severity relationship 
appears to account for approximately 20% of the 
total variance associated with the DST (9-14). The 
rating scales that are used for these types of investi- 
gations (most often the 17-item Hamilton Rating 
Scale for Depression (HRSD) (34)), however, are 
composed of many symptoms. We undertook this 
study to determine which of the items that comprise 
clinically defined severity of depressive illness 
account for the relationship between postdexa- 
methasone plasma cortisol levels and severity of de- 
pression. 
Material and methods 
Subjects 
A total of 114 patients of the Clinical Studies Unit 
(CSU) of the University of Michigan Depression 
Program of the Department of Psychiatry at the 
University of Michigan Medical Center were 
studied. Patients admitted to CSU undergo an 
extensive diagnostic evaluation, including 2 or more 
unstructured clinical interviews by psychiatrists, a 
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structured diagnostic interview using the Schedule 
for Affective Disorders and Schizophrenia (SADS) 
(35) by a trained research st& member, and a 
detailed family and social assessment by a staff 
social worker. Additionally, patients receive a 
thorough physical and laboratory examination, 
which routinely includes an electrocardiogram, com- 
plete blood count, electrolytes, tests of hepatic, pan- 
creatic, renal and thyroid functions, plasma vitamin 
B,, and folate levels, VDRL, and a urine drug 
screen. At the conclusion of the assessment period, 
diagnosis is formulated by consensual agreement of 
involved clinicians using Research Diagnostic Crite- 
ria (RDC) (36). Patients included in this study were 
patients at CSU during the years 1981-1986. 
Inclusion criteria were: patients met RDC for 
major depressive disorder (MDD); none were of the 
psychotic subtype; all underwent at least a 2-week 
medication-free washout period; each had a 1-mg 
oral dexamethasone suppression test at the con- 
clusion of the drug-free period (baseline); none had 
identifiable technical exclusions that might invalidate 
DST results; and each gave written informed con- 
sent to participate in these research activities. The 
characteristics of this patient population are sum- 
marized in Table 1. In addition to this baseline data, 
a subgroup of patients (n = 66) was systematically 
monitored during treatment with weekly DST and 
HRSD scores. This subgroup of the total population 
was further studied to assess cortisol and severity 
rating scale changes over time. 
Laboratory procedures 
DST was administered in a standardized manner (1, 
37). Patients received 1 mg dexamethasone orally at 
2330, and plasma was obtained at 0800, 1600, and 
2300 on the following day. Plasma cortisol was 
determined by a modification of Murphy’s (38) com- 
petitive protein-binding technique. Prior to use of 
parametric statistics, the maximum postdexametha- 
sone plasma cortisol levels underwent logarithmic 
transformation to improve normality of distribution. 
Table 1. Clinical and demographic characteristics of study patients 
Variable Mean f SD Range 
Age (years) 
Recent weight change (kgl 
HRSD score 
Past depressive episodes 
Age, first depressive episode 





42.4 f 16.4 19-85 
-0.7 & 9.3 -25-+40 
19.2 * 10.9 9-34 
2.5 3.0 0-8 (or more) 
32.7 f 15.7 12-80 





Each patient was rated for severity of depression 
using the 17-item HRSD (34) within 2 days of the 
DST by a clinician who was blind to all 
neuroendocrine measures, including current and 
previous DST results. The interrater reliability of the 
HRSD is studied at CSU every 6 months, and has 
consistently been within 2 points. 
Data analysis 
This database is stored within the University of 
Michigan Central Computer Facility on an IBM 
3090-400 Mainframe, which houses the Michigan 
Terminal System. Statistical analysis was performed 
using the Michigan Interactive Data Analysis Sys- 
tem (MIDAS) software package. 
Results 
Relationships between baseline severity and cortisol 
To study the relationship between severity of de- 
pression and postdexamethasone plasma cortisol 
levels at baseline, Pearson’s product-moment corre- 
lation coefficients were calculated for total HRSD 
scores and logarithmically transformed postdexame- 
thasone plasma cortisol levels. As we and others 
have previously shown (9-14), these 2 variables are 
significantly correlated (n = 114, Y = 0.38, 
P < 0.0001). To determine which of those items 
comprising the HRSD are responsible for this re- 
lationship, correlation coefficients were calculated 
between individual HRSD item scores and post- 
dexamethasone plasma cortisol levels. Significant 
relationships were found between postdexametha- 
sone plasma cortisol and middle and delayed 
insomnia, agitation, psychological and somatic 
anxiety, gastrointestinal and genital symptoms, loss 
of insight and weight loss (Table 2). 
As 9 of the 17 HRSD items appeared to be signifi- 
cantly related to postdexamethasone plasma cortisol 
levels, it seemed possible that relationships between 
postdexamethasone plasma cortisol and any given 
HRSD item score might be confounded by the re- 
lationship of that variable to another HRSD item. 
To further explore this, the degree of association 
between the HRSD items themselves was explored. 
Table 3 demonstrates the matrix generated by corre- 
lating each HRSD item with the remaining items; 
only significant relationships are indicated. Many 
items are related to other items comprising the total 
HRSD score, and each item is significantly cor- 
related with at least one other item. Because of the 
high degree of multicollinearity among HRSD 
variables, we attempted to simplify these items into 
less interrelated factors. Principal component 
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Table 2. Coefficients of correlation between HRSD items and postdexamethasone 
plasma cortisol levels at baseline 















































analysis was employed to generate orthogonal 
underlying factors, to determine whether any of these 
9 items might contribute more than others to the 
relationship between HRSD and postdexametha- 
sone plasma cortisol. Several methods are available 
to calculate such factors. Principal component ana- 
lysis was selected instead of factor analysis; factor 
analysis requires that assumptions be made on the 
nature of the underlying factors as well as of a proper 
model, which may be quite difficult in practice. On 
the other hand, principal component analysis re- 
quires no assumptions of the underlying compo- 
nents, but simply generates orthogonal factors by a 
mathematical procedure. Accordingly, given the na- 
ture of this study, we felt the more conservative 
principal component analysis to be a more appro- 
priate method of generating these factors (39). 
Table 3. Correlation matrix of HRSD items at baseline 
Table 4 presents the results of this principal com- 
ponent analysis. Only the first 4 principal compo- 
nents generated were significant with eigenvalues 
> 1.00; these 4 components accounted for 54% of 
the total variance. To determine which, if any, of 
these principal components are related to post- 
dexamethasone plasma cortisol levels, coefficients of 
correlation were determined for each component 
and plasma cortisol. These results are summarized 
in Table 5. Only the first component exhibited a 
significant relationship with postdexamethasone 
plasma cortisol (n = 114, Y = 0.37, P < O.OOOl), 
having essentially the same degree of association 
with postdexamethasone plasma cortisol as the 
original total HRSD score (Y = 0.38). 
Examination of the first principal component re- 
Table 4. Principal component analysis of individual HRSD items at baseline 
Component 1 II 111 IV 
Eigenvalue 
Percentage of variance 





























































1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
1. Depressed mood 
2. Guilt 
3. Suicide 
4. Initial insomnia 
5. Middle insomnia 
6. Delayed insomnia 
7. Work and interest 
8. Retardation 
9. Agitation 
10. Psychological anxiety 
1 1. Somatic anxiety 
12. Gastrointestinal 
13. General somatic 
14. Genital 
15. Hypochondriasis 
16. Loss of insight 
17. Weight loss 
0.28 
0.38 0.35 
- -  
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0.18 - 





























HPA dysregulation and severity of MDD 
Table 5. Coefficients of correlation between postdexamethasone plasma cortisol levels 
and principal components of HRSD items at baseline 
Principal component 1 P 
I 0.37 < 0.000 1 
II -0.15 NS 
111 0.17 NS 
IV 0.10 NS 
veals that the primary contributing HRSD items are 
somatic and psychological anxiety, both of which 
were found to be in the group of 9 HRSD items 
significantly correlated with postdexamethasone 
plasma cortisol levels. Seemingly, then, the 2 anxiety 
components of the HRSD appear to contribute 
significantly to the observed relationship between 
HRSD and postdexamethasone plasma cortisol. 
Linear regression analysis revealed that the sum of 
the 2 anxiety components of the HRSD contribute 
a large percentage of the variance observed in the 
relationship between total severity and postdexame- 
thasone plasma cortisol. With logarithmically trans- 
formed postdexamethasone plasma cortisol as the 
dependent variable, and the combined anxiety scores 
from the HRSD and the HRSD less these 2 anxiety 
scores as independent variables, a significant linear 
relationship was established (multiple Y = 0.39, 
F = 9.95, df = 2,113, P < 0.0001). Each of the inde- 
pendent variables has a significant partial correlation 
coefficient (anxiety items, Y = 0.21, P < 0.02; anxie- 
ty-corrected HRSD, Y = 0.27, P < 0.005). Thus, the 
anxiety items appear to contribute about half of the 
variance to the relationship between severity of de- 
pression and postdexamethasone plasma cortisol 
levels at baseline. 
Relationships between longitudinal severity and cortisol 
As these baseline studies suggested that the relation- 
ship between severity and cortisol was largely 
explained by the anxiety components of the HRSD, 
the relationships of postdexamethasone plasma cor- 
tisol, severity of depression ratings, and anxiety 
ratings were studied over time. Weekly changes in 
postdexamethasone plasma cortisol, anxiety-cor- 
rected HRSD scores (HRSD scores less psychologi- 
cal and somatic anxiety scores), and combined 
HRSD anxiety item scores (somatic and psychologi- 
cal anxiety) were compared by analysis of variance. 
Figs. 1-3 summarize the changes of logarithmically 
transformed postdexamethasone plasma cortisol 
(Fig. l), anxiety-adjusted HRSD scores (Fig. 2), and 
the sum of the anxiety items from the HRSD (Fig. 3) 
over time. All 3 measures decrease over time in 
parallel; all first are significantly less than their re- 
spective baseline measures at week 4, and remain so 
N=114 62 65 66 62 46 36 26 
225 1 
200 1 T 
50 a 
25 01 0 2 4 6 8 
weeks 
Fig. 1 .  Longitudinal course of postdexamethasone plasma corti- 
sol from baseline through week 8 of treatment. Cases are not 
complete after week 1, and the number of patients remaining at 
each week are shown at the top of the figure. Results are means 
f SE; *significantly different from baseline measure (P < 0.05). 
c 
6 (  I I I 1 
0 2 4 6 8 
weeks 
Fig. 2 .  Longitudinal course of anxiety-adjusted total HRSD 
scores from baseline through week 8 of treatment. For number 
of patients studied at each time point, see Fig. 1. Results are 
means f SE; *significantly different from baseline measure 
(P < 0.05). 
(with the sole exception of cortisol in week 7) for the 
8 weeks surveyed. 
To further address the longitudinal nature of these 
items, correlation coefficients were calculated at 
baseline, 4 weeks into treatment, and at discharge. 
At baseline, somatic and psychological anxiety were 
significantly correlated with postdexamethasone 
plasma cortisol, and were the 2 factors with the 
heaviest loading in the only principal component of 
the 17 HRSD items significantly correlated with 
postdexamethasone plasma cortisol. Fig. 1 reveals 
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4 1  T 
* I  I I I I 
0 2 4 6 a 
weeks 
Fig. 3. Longitudinal course of the sum of both HRSD anxiety 
items from baseline through week 8 of treatment. For number of 
patients studied at each time point, see Fig. 1. Results are means 
- + SE; *significantly different from baseline measure (P < 0.05). 
that the earliest time at which postdexamethasone 
plasma cortisol is significantly less than at baseline 
is week 4. Correlation coefficients for postdexame- 
thasone plasma cortisol and total and individual 
HRSD items at week 4 are demonstrated in Table 6. 
Total HRSD remains Significantly correlated with 
postdexamethasone plasma cortisol (r = 0.24, 
n = 65, P < 0.05). Of the 17 HRSD items, only so- 
matic anxiety is correlated with postdexamethasone 
plasma cortisol. By the time of discharge, total 
HRSD score is no longer correlated with post- 
dexamethasone plasma cortisol. As long as HRSD 
scores remain correlated with postdexamethasone 
plasma cortisol levels, the anxiety components 
Table 6. Coefficients of correlation between HRSD items and postdexamethasone 
plasma cortisol levels at week 4 
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appear to contribute significantly to the relationship. 
To address the possibility of interactions of post- 
dexamethasone plasma cortisol and combined 
HRSD anxiety item scores over time, profile analysis 
was used (40). Profile analysis is a longitudinal sta- 
tistical method that allows comparisons of and elu- 
cidation of interactions of variables over time. In this 
particular case, logarithmically transformed post- 
dexamethasone plasma cortisol was studied longitu- 
dinally at weekly intervals for weeks 1-6. The popu- 
lation was divided into thirds by HRSD somatic and 
psychological anxiety combined scores, corre- 
sponding to low, moderate, and high levels of anxiety 
on HRSD. These 3 groups were divided into 
subgroups with pretreatment anxiety total scores of 
0-1 (low anxiety, n = 11), 2-3 (moderate anxiety, 
n = 46), and 4-8 (high anxiety, n = 60). Although 
the subgroups appear to have different numbers of 
patients at baseline, by week 2 all 3 groups were of 
similar size. The change in the 3 anxiety level profiles 
was examined over time for the entire population. In 
profile analysis, the first test is to determine if the 
profiles are parallel; nonparallelism of profiles in this 
particular study indicates significant anxiety x time 
interaction. If profiles are parallel, hence the pattern 
of change similar over time for all anxiety subgroups, 
one is able to then test for possible significant anxiety 
differences within the test group, as well as differ- 
ences between groups over time. 
The results of this analysis are shown in Table 7 
and Fig. 4. For the entire population, the 3 profiles 
are parallel, hence there is no significant time x 
anxiety interaction. A significant (P  < 0.05) 
between-group (anxiety) difference exists, as does a 
significant (P  < 0.0001) main effect for time. Over 
time, postdexamethasone plasma cortisol decreases 
significantly, regardless of the anxiety stratum an 
individual is in. All 3 anxiety groups manifest this 
tendency, and all 3 change in a similar fashion over 
time. The high anxiety subgroup begins with the 
highest cortisol levels, however, followed by the 
moderate and then the low anxiety groups; this 
Table 7. Profile analysis of time and anxiety factors for longitudinal postdexamethasone 
plasma cortisol data 
Parallelism of profiles 
Maximum root = 0.052 
df = 2’1,116 
NS 
Time 
F = 30.1 
df = 5,234 




df = 2,238 
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Ill. high anxiety 
I, low anxiety 
11, moderate anxiety 
weeks 
Fig. 4. Profile analysis of postdexamethasone plasma cortisol levels for low (I), medium (11), and high (111) anxiety groups over 
weeks 1-6. 
relative relationship remains constant over time, 
despite the reduction in cortisol for all 3 groups. High 
pretreatment levels of anxiety (as reflected by HRSD 
anxiety items) then suggests that individuals will 
manifest relatively higher plasma cortisols over time 
than patients with lower levels of anxiety, although 
all patients tend to have a longitudinal reduction of 
cortisol during treatment. This finding implies a 
longitudinal correlation between postdexametha- 
sone plasma cortisol and anxiety. 
Discussion 
These results replicate and extend previous studies 
demonstrating a relationship between postdexame- 
thasone plasma cortisol levels and severity of depres- 
sive symptoms, as reflected by depression rating 
scale scores, in major depressive disorder (9-19). 
Similar to previous estimates, severity of depression 
was found to account for as much as 15-20% of the 
variance associated with DST (9-14). As indicated 
by the data from these 114 subjects, a significant 
portion of this relationship was found to be attribut- 
able to the anxiety symptoms of the HRSD at pre- 
treatment baseline. Additionally, this association 
was preserved longitudinally over time, during treat- 
ment for depression. 
Several previous investigations have attempted to 
identify depressive symptoms associated with 
dexamethasone nonsuppression in patients with 
affective disorders. Results of this type of study have 
been equivocal, and have been recently reviewed (9). 
Symptom differences that appear to be moderately 
consistent from study to study between dexametha- 
sone suppressors and nonsuppressors include 
various patterns of insomnia (9, 15-17), weight loss 
(9, 15), and psychomotor agitation and retardation 
(9, 17, 19). Some investigators have variably found 
differences in anxiety levels (15-17, 19), lack of 
sexual interest (9, 16), decreased concentration 
(15, 16), and depressed mood (15). These results 
should be compared cautiously, however, since the 
studies often had small numbers of subjects, 
employed different experimental designs, and used 
different rating scales. No single items have been 
consistently demonstrated as being significantly 
different between dexamethasone suppressors and 
nonsuppressors. 
More recently, various investigators have de- 
monstrated that there is a modest but significant 
correlation between total severity of depression (as 
reflected by various rating scales) and postdexame- 
thasone plasma cortisol levels. These studies have 
been remarkably consistent, indicating that 15-20 % 
of the total variance associated with DST is attribut- 
able to clinical severity (9-14). In addition to this 
relationship at the adrenal level of the HPA axis, we 
have reported a similar correlation between severity 
of depression and circulating levels of the pituitary 
hormone, P-endorphin, following dexamethasone 
(1 1). Our present data are in agreement with these 
previous studies. 
One recent study (9) has been reported in which 
a strategy similar to ours was employed. In this 
report, however, the authors found that the Yale 
Depression Inventory items of initial insomnia, agi- 
tation, loss of sexual interest, and weight loss were 
associated with dexamethasone nonsuppression and 
postdexamethasone plasma cortisol levels, whereas 
the 2 anxiety items on this particular rating instru- 
ment were not. At baseline, we did find associations 
between postdexamethasone plasma cortisol and the 
4 items reported in this earlier study, but the main 
effect nonetheless appeared to be related to psycho- 
logical and somatic anxiety. The discrepancy 
between this previous report and the present data is 
difficult to reconcile; both studies evaluated similar 
numbers of patients, and while this earlier report 
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appeared to have a more heterogeneous study popu- 
lation, it is doubtful that this is sufficient to account 
for these different findings. These authors did indi- 
cate in their review of previous studies in this area 
that the association between anxiety and cortisol 
levels has historically been equivocal. 
Interestingly, many studies have been designed to 
explore the naturalistic clustering of depression 
rating scale scores in depressed individuals. A recent 
review (41) of 40 of these studies in which principal 
component analysis was used to explore this phe- 
nomenon concluded that, in every study, factor clus- 
ters existed for both depressive symptoms and anxie- 
ty symptoms. Interestingly, one of these studies was 
by Hamilton (42), using his 17-item HRSD. Two 
major orthogonal factors were identified in a group 
of 152 patients: Hamilton labelled these as a general 
measure of severity item (I) and a retarded vs agitated 
depression item (11). The heaviest loadings of these 
factors were, however, identified for I as suicide, 
depressed mood, work and interest, loss of insight, 
and retardation, and for I1 as somatic anxiety and 
psychic anxiety. These 2 factors found by Hamilton 
correspond very closely to factors I1 and I, respec- 
tively, in the present study. Indeed, our finding that 
the first 2 principal components consist of an anxiety 
component and a depression component replicates 
many early studies designed to explore underlying 
principal components of depression rating scales. It 
is intriguing that baseline postdexamethasone plas- 
ma cortisol was found to correlate with the anxiety 
component rather than the depression component; 
in fact, the magnitude of this correlation was the 
same as for total severity, suggesting that this com- 
ponent itself accounts for all of the variance asso- 
ciated with severity of depression and postdexame- 
thasone plasma cortisol levels. 
Finally, our data may provide some basis for 
another conceptual formulation of the hypo- 
thalamic-pituitary-adrenal axis dysregulation seen in 
depression. It has long been recognized that the 
HPA axis is the basic stress system, in effect 
protecting the organism from the deleterious effects 
of repeated stress (43-45). What has also become 
apparent is that patients with affective disorders 
share certain neuroendocrine similarities with endo- 
crine disturbances associated with stress (1, 3, 4, 
43-45). It is tempting to speculate that the anxiety 
components of the HRSD may reflect the subjective 
experience of stress in affected individuals, and 
hence the relationship between severity of depression 
and postdexamethasone plasma cortisol mirrors the 
degree of stress an individual with depression per- 
ceives. Clearly, this is tentative and requires further 
investigation. 
The HPA axis is a complex system that is robustly 
dysregulated in certain depressed individuals. Seve- 
rity of illness (9-19), age (20-23), degree of recent 
weight loss (24, 25), and the presence of delusions 
(26,29) appear to be the major sources of variance 
associated with this pathophysiological alteration. 
The exact cause of this neuroendocrine defect in the 
affective disorders has eluded characterization, but 
may reflect central neurotransmitter and 
neuromodulator disturbances associated with de- 
pression. As data are collected on large populations 
of patients, however, studies such as this can be 
undertaken to begin to find the factors that either 
cause or modulate this endocrine disturbance; in this 
way, we can hopefully begin to more fully com- 
prehend the chemical disturbances underlying the 
affective and other psychiatric disorders. 
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